| Objective To observe the effects of liraglutide on body mass and insulin resistance in the overweight and obese patients with type 2 diabetes.Methods From Jun 2012 to Jan 2014, ninety cases of patients with type 2 diabetes hospitalized in our hospital, which were poorly controlled by oral hypoglycemic drugs with body mass index (BMI)≥24 kg/m2, were divided into the treatment group (45 cases) and the control group (45 cases) by randomized system. The treatment group was further divided into two subgroups according to their BMIs:the overweight subgroup (BMI < 28 kg/m2, 24 cases) and the obese subgroup (BMI≥28 kg/m2, 21 cases). Besides the original therapy regimen, the control group was given basal insulin and the treatment group with liraglutide, lasting for 12 weeks. After treatment, the changes of such indicators (BMI, systolic blood pressure, fasting blood glucose, postprandial blood glucose, etc.) between them were compared.Results In the treatment group, the results of BMI and homeostasis model assessment of insulin resistance (HOMA-IR) were significantly fewer after treatment than those before treatment (P<0.05), but these results in the control group were significantly increased after treatment (P<0.05). The levels of systolic blood pressure (SBP), fasting blood glucose (FPG), 2-hour postprandial glucose (2hPG), glycosylated hemoglobin (HbA1c), triglyceride (TG) and total cholesterol (TCh) decreased significantly in both groups after treatment (all P<0.05), and there were significant differences in the decline of SBP, TG and TCh levels between the two groups (P<0.05), but no significant difference was found in the decline of FPG, 2hPG and HbA1c between the two groups (P>0.05). In the treatment group, BMI of the obese subgroup dropped more significantly than that of the overweight subgroup (P<0.05). There was no severe hypoglycemia in both groups during treatment. Conclusion For those overweight and obese patients with type 2 diabetes, liraglutide could play an important role in reducing blood glucose, and further decreasing their body mass and improving their insulin resistance. And when the baseline BMI is higher, the effects of liraglutide in decreasing body mass and improving insulin resistance would be stronger. |
